Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst
Portfolio Pulse from Vandana Singh
Cantor Fitzgerald has downgraded Editas Medicine Inc (EDIT) to Neutral from Overweight due to competition in sickle cell therapy. Editas' EDIT-301 is running two years behind Vertex Pharmaceuticals/CRISPR Therapeutics AG's (CRSP) exa-cel and Bluebird Bio Inc's (BLUE) lovo-cel. The development of EDIT-301 is expected to be associated with limited value creation. EDIT shares are down 4.68% at $6.92.
October 17, 2023 | 6:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bluebird Bio Inc's lovo-cel is ahead of Editas Medicine Inc's EDIT-301 in the development of sickle cell therapy.
Bluebird Bio Inc's lovo-cel is ahead in the development of sickle cell therapy, which could potentially lead to a larger market share and increased profitability.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 60
POSITIVE IMPACT
Vertex Pharmaceuticals/CRISPR Therapeutics AG's exa-cel is ahead of Editas Medicine Inc's EDIT-301 in the development of sickle cell therapy.
CRISPR Therapeutics AG's exa-cel is ahead in the development of sickle cell therapy, which could potentially lead to a larger market share and increased profitability.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 60
NEGATIVE IMPACT
Editas Medicine Inc has been downgraded by Cantor Fitzgerald due to competition in sickle cell therapy. Its EDIT-301 is running two years behind competitors' therapies.
The downgrade by Cantor Fitzgerald is due to the competition in sickle cell therapy. Editas' EDIT-301 is running two years behind its competitors' therapies, which could limit its market share and profitability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100